The Oncomine Dx Target Test as a companion diagnostic has received FDA approval to identify RET fusion-positive, metastatic non-small cell lung cancer patients who are candidates for Gavreto (pralsetinib), a targeted therapy developed by Blueprint Medicines.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.